Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2NET 1

Conditions

Neuroblastoma 12Pheochromocytoma 4Neoplasms 3Recurrence 2Paraganglioma 2Neuroendocrine Tumors 2Neuroectodermal Tumors 1Neoplasm Metastasis 1Ganglioneuroblastoma 1

Interventions

lutetium Lu 177 dotatate 4Temozolomide 4anlotinib 3Specimen Handling 3cabozantinib 2belzutifan 2Sunitinib 2Magnetic Resonance Spectroscopy 2Axitinib 23-Iodobenzylguanidine 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2talazoparib 1pembrolizumab 1pazopanib 1olaparib 1lanreotide 1guadecitabine 1gallium Ga 68 dotatate 1copper dotatate CU-64 1atezolizumab 1ONC206 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Paraganglioma × 3-Iodobenzylguanidine × Clear all
NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Phase 2 Unknown
74 enrolled 10 charts 1 FDA
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT01413503 2018-09-18

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

University of California, San Francisco

Phase 2 Completed
50 enrolled 7 charts
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡